Cannabidiol

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-09-07srcCannabinoids for Medical Use: A Systematic Review and Meta-analysis
4. 2026-09-07srcConsensus panel recommendations for the optimization of EPIDIOLEX treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
5. 2026-09-07srcShort-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise
6. 2026-09-07srcEvaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews
7. 2026-09-07srcCannabidiol as a Potential Treatment for Anxiety Disorders
8. 2026-09-07srcComparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru, vs an Oil-Based Formulation, Epidyolex, Under Fasted and Fed Conditions in Healthy Participants
9. 2026-09-07srcSpecies differences in pregnane X receptor activation by delta-9-tetrahydrocannabinol, cannabidiol, and cannabinol
10. 2026-09-07srcCannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum
11. 2026-09-07srcFunctional selectivity of cannabinoids at CB1 receptors: Comprehensive analysis of G proteins, beta-arrestin and cAMP signalling dynamics in HEK293T cells
12. 2026-09-07srcCannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery
13. 2026-09-07srcIn silico insights on the binding site and function of cannabinoids and cannabinoid acids on human 5-HT1A receptor
14. 2026-09-07srcCannabinoid-based interventions for behavioral outcomes in children and adolescents with autism spectrum disorder: A systematic review
15. 2026-09-07srcEffect of cannabidiol and hemp extract on viability and function of hepatocytes derived from human induced pluripotent stem cells
16. 2026-09-07srcEstablishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids
17. 2026-09-07srcComparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids
18. 2026-09-07srcThe efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis
19. 2026-09-07srcPharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
20. 2026-09-07srcMolecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
21. 2026-09-07srcThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin
22. 2026-09-07srcCannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
23. 2026-09-07srcPhytocannabinoids: a unified critical inventory
24. 2026-09-07srcTrial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
25. 2026-09-07srcEffect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
26. 2026-09-07srcCannabidiol Interferes with Establishment of delta9-Tetrahydrocannabinol-Induced Nausea Through a 5-HT1A Mechanism
27. 2026-09-07srcCannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
28. 2026-09-07srcCitalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People
29. 2026-09-07srcThe pharmacokinetics and the pharmacodynamics of cannabinoids
30. 2026-09-07srcCoadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
31. 2026-09-07srcClinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs
32. 2026-09-07srcLong-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial
33. 2026-09-07srcAdd-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial (GWPCARE5)
34. 2026-09-07srcTime to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of GWPCARE6
35. 2026-09-07srcEffects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
36. 2026-09-07srcMedicinal Use of Cannabis: History and Current Status
37. 2026-09-07srcCannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
38. 2026-09-07srcThe therapeutic potential of purified cannabidiol
39. 2026-09-07srcAbuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex)
40. 2026-09-07srcPharmacokinetics and Pharmacodynamics of Cannabinoids
41. 2026-09-07srcUpdate of the statement on safety of cannabidiol as a novel food
42. 2026-09-07srcCannabidiol Acts at 5-HT1A Receptors in the Human Brain: Relevance for Treating Temporal Lobe Epilepsy
43. 2026-09-07srcResults From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome
44. 2026-09-07srcEpilepsy, neuroinflammation and cannabidiol What do we know thus far?
45. 2026-09-07srcA critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids
46. 2026-09-07srcPharmacological and Pharmacokinetic Profile of Cannabidiol in Human Epilepsy: A Review of Metabolism, Therapeutic Drug Monitoring, and Interactions with Antiseizure Medications
47. 2026-09-07srcMedical Marijuana and Treatment Personalization: The Role of Genetics and Epigenetics in Response to THC and CBD
48. 2026-09-07srcCBD in the Treatment of Epilepsy
49. 2026-09-07srcPharmacokinetics of cannabinoids
50. 2026-09-07srcAgonistic properties of cannabidiol at 5-HT1a receptors
51. 2026-09-07srcCannabinoid pharmacology: the first 66 years
52. 2026-09-07srcCannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
53. 2026-09-04issueIssued emergency
54. 2026-09-04issueIssued info_card
55. 2026-09-04issueIssued notice
56. 2026-06-04proposal27 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
57. 2026-06-04publicationPublication — backfill
58. 2026-05-07revisionRevision 1
59. 2026-05-07absenceSearched PubMed for "cannabidiol discovery history isolation Adams mechoulam 1940 1963" — no results
60. 2026-05-07genGeneration — pipeline-v5 · with 2 morepipeline-v5
61. 2026-05-07rungeneration run

The same entries, as forms: six forms.